High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy

Gynecological Endocrinology

Volumn 26, Issue 7, 2010, Pages 524-532

  Labrie, Fernand ^a,b   Archer, David ^c   Bouchard, Céline ^d   Fortier, Michel ^d   Cusan, Leonello ^a   Gomez, José Luis ^a   Girard, Ginette ^e   Baron, Mira ^f   Ayotte, Normand ^g   Moreau, Michle ^h   Dubé, Robert ^a   Côté, Isabelle ^b   Labrie, Claude ^a,b   Lavoie, Lyne ^b   Berger, Louise ^b   Martel, Céline ^b   Balser, John ⁱ  

^a LAVAL UNIVERSITY   (Canada)

^b Endoceutics Inc   (Canada)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d Clinique de Recherche en Sante des Femmes   (Canada)

^e Diex Recherche Inc   (Canada)

^f Rapid Medical Research   (United States)

^g Clinique Gynecologique   (Canada)

^h CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

ⁱ Veristat Inc   (United States)

Author keywords

Dhea; Intracrinology; Prasterone; Tissue specific prehormone replacement therapy; Vaginal atrophy

Indexed keywords

ESTROGEN DERIVATIVE; PRASTERONE; UNCLASSIFIED DRUG; VAGINORM;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; ESTROGEN BLOOD LEVEL; FEMALE; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; PH; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; VAGINA ATROPHY; VAGINA PAIN;

ADMINISTRATION, INTRAVAGINAL; ATROPHY; DEHYDROEPIANDROSTERONE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; POSTMENOPAUSE; TREATMENT OUTCOME; VAGINA; VAGINAL DISEASES;

EID: 77953644257     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590903511547     Document Type: Article

References (20)

1. N.A.M.S. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 Position Statement of the North American Menopause Society. Menopause 2007;14:357-369.
2. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:156-161.
3. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006;17: 584-587.
4. Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bé langer P, Martel C, Labrie C, Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009;16:30-36.
5. Labrie F, Luu-The V, Bé langer A, Lin S-X, Simard J, Labrie C. Is DHEA a hormone? Starling Review. J Endocrinol 2005; 187:169-196.
6. Labrie F. Drug insight: breast cancer prevention and tissuetargeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab 2007;3:584-593.
7. Labrie F, DHEA after Menopause - Sole source of sex steroids and potential sex steroid deficiency treatment. Menopause Management 2010;19:14-24.
8. Labrie F, Bé langer A, Bé langer P, Bérubé R, Martel C, Cusan L, et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 2006;99:182-188.
9. Berger L, El-Alfy M, Martel C, Labrie F. Effects of dehydroepiandrosterone, premarin and acolbifene on histomorphology and sex steroid receptors in the rat vagina. J Steroid Biochem Mol Biol 2005;96:201-215.
10. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause, 2009;16:907-922.
11. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard D, Baron M, Ayotte N, Moreau M, et al. Effect on intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause, 2009;16:923-931.
12. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause 2009;16:897-906.
13. Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bé langer P, et al. Corrigendum to: Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008;112:169.
14. Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bé langer P, et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008;111:178-194.
15. Meisels A. The maturation value. Acta Cytol 1967;11:249.
16. Wied GL. Industrial developments in automated cytology as submitted by their developers. Anal Quant Cytol Histol 1993;15:358-370.
17. Labrie F, Diamond P, Cusan L, Gomez JL, Belanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997;82:3498-3505.
18. Calvo E, Luu-The V, Morissette J, Martel C, Labrie C, Bernard B, et al. Pangenomic changes induced by DHEA in the skin of postmenopausal women. J Steroid Biochem Mol Biol 2008;112:186-193.
19. Labrie F, Cusan L, Gomez JL, Martel C, Berube R, Belanger P, Chaussade V, Deloche C, Leclaire J. Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA. J Steroid Biochem Mol Biol 2008;110:1-9.
20. Suh-Burgmann E, Sivret J, Duska LR, Del Carmen M, Seiden MV. Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia - a pilot study. Gynecol Obstet Invest 2003;55:25-31.